Merck KGaA's Erbitux Faces Hurdle - Analyst Blog - NASDAQ

Merck KGaA ( MKGAF) recently reported disappointing interim data from a late-stage study (PETACC-8) on Erbitux (cetuximab), which is being evaluated as an adjuvant treatment of stage III colon cancer. The data did not support the use of the drug ...

Merck PETACC-8 Study of Erbitux as Adjuvant Treatment in Colon Cancer Shows no Benefit at Pre-specified Interim Analysis - Phramalive.com

Pre-specified interim analysis of Phase III pan-European trial in patients with KRAS wild-type colon cancer does not show improvements in disease free survival Darmstadt, Germany, May 9, 2012 – Merck announced today results from an interim analysis of ...

Merck KGaA Says Erbitux Showed No Benefit After Surgery - Bloomberg

Merck KGaA (MRK)’s Erbitux showed no benefit in patients with stage-three colon cancer when given with standard chemotherapy after their tumors were removed, compared with chemotherapy alone, according to a study. Patients in the clinical ...

Merck KGaA Says PETACC-8 Study Of Erbitux Shows No Benefit At Interim Analysis - RTT News

(RTTNews) - Merck KGaA (MKGAY.PK: News ) revealed results from an interim analysis of the Phase III clinical trial PETACC-81. The study investigated the potential clinical utility of Erbitux (cetuximab) for the adjuvant treatment of stage III colon cancer ...

Combination Of Lapatinib With Cetuximab To Overcome Resistance In EGFR-Driven Tumors: Study - Med India

GlaxoSmithKline provided lapatinib for the study and additional financial support for the study. Cetuximab, marketed as Erbitux, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of metastatic colorectal cancer ...

Merck KGaA's Erbitux fails in colon cancer study - msnbc.com

FRANKFURT (Reuters) - Germany's Merck KGaA said on Wednesday that Erbitux, one of its most important drugs, failed to help colon cancer patients after surgery in a late stage trial. A scheduled interim analysis of the so-called Petacc-8 study ...

Idera Pharmaceuticals Reports First Quarter 2012 Financial Results - TMCnet

Top-line Data Announced from a Phase 2 Trial of IMO-2055 in Combination with Erbitux ® in Second-Line Erbitux-Naïve Subjects with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) In the second quarter of 2012 ...

ImClone Systems Incorporated: Pharmaceuticals and Healthcare Company Profile & SWOT Report - new company profile report - Transworld News

The company is principally focused on growth factor blockers and angiogenesis inhibitors for treating a variety of cancers. Erbitux, a type of therapeutic monoclonal antibody is the trademark product of ImClone. The company has granted Merck KgaA ...

Head and neck cancer: Cetuximab in combination with Docetaxel and Cisplatin as induction therapy - Xagena Medical News

Patients treated for locally advanced head and neck cancer may respond better to treatment with the addition of Cetuximab ( Erbitux ) to chemotherapy, according to a phase II study. In the study, 39 patients with stages 3 or 4 head and neck cancer were ...

New Data from Bristol-Myers Squibb Oncology Portfolio to be Presented at 2012 American Society of Clinical Oncology (ASCO) Annual Meeting - Yahoo Finance

In three patients with prior history of coronary artery disease, death occurred 27, 32, and 43 days after the last dose of ERBITUX. One patient with no prior history of coronary artery disease died one day after the last dose of ERBITUX.